On Mar. 5, 2021, Abivax announced tthat it was halting the miR-AGE phase 2b/3 clinical trial in high-risk Covid-19 patients after the independent Data Safety and Monitoring Board (DSMB) recommendation for lack of efficacy. The multinational miR-AGE ABX464 phase 2b/3 clinical trial (ABX464-401), had recruited 500 high-risk Covid-19 patients out of the planned 1,034 and has been declared ﾓResearch National Priorityﾔ by the French government in December 2020.